Financial Contrast: Avant Diagnostics (AVDX) vs. Celcuity (CELC)

Celcuity (NASDAQ:CELC) and Avant Diagnostics (OTCMKTS:AVDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.


This table compares Celcuity and Avant Diagnostics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celcuity N/A -26.03% -25.25%
Avant Diagnostics N/A -143.01% -51.41%

Volatility and Risk

Celcuity has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Avant Diagnostics has a beta of 10.7, indicating that its stock price is 970% more volatile than the S&P 500.

Valuation & Earnings

This table compares Celcuity and Avant Diagnostics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celcuity N/A N/A -$7.48 million ($0.74) -29.51
Avant Diagnostics $250,000.00 8.09 -$2.37 million N/A N/A

Avant Diagnostics has higher revenue and earnings than Celcuity.

Analyst Recommendations

This is a summary of current recommendations for Celcuity and Avant Diagnostics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity 0 0 2 0 3.00
Avant Diagnostics 0 0 0 0 N/A

Celcuity presently has a consensus price target of $35.50, indicating a potential upside of 62.55%. Given Celcuity’s higher possible upside, analysts clearly believe Celcuity is more favorable than Avant Diagnostics.

Institutional & Insider Ownership

21.9% of Celcuity shares are owned by institutional investors. Comparatively, 0.0% of Avant Diagnostics shares are owned by institutional investors. 43.5% of Celcuity shares are owned by company insiders. Comparatively, 38.0% of Avant Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


Celcuity beats Avant Diagnostics on 6 of the 9 factors compared between the two stocks.

Celcuity Company Profile

Celcuity Inc., a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the clinical outcomes of cancer patients treated with targeted therapies in the United States. The company's CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is developing CELx HSF test to diagnose two new sub-types of HER2-negative breast cancer. The company is also developing CELx MP test to diagnose 12 new potential cancer sub-types in breast, lung, colon, ovarian, kidney, and bladder cancers. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Avant Diagnostics Company Profile

Avant Diagnostics, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic tests that provide information for physicians and patients in the areas of cancers. It offers OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.

Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with's FREE daily email newsletter.